An Exploratory Clinical Study of Dalpiciclib an'd Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

StatusUnknown
PhaseNot applicable
SponsorLiu Shu
Started

Record status This record was last updated September 20, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Liu Shu
3 trials monitored
See all monitored trials
Breast Cancer
5,455 trials monitored
See 306 trials at risk
This is a single-arm, open-label, exploratory clinical study
Trial Details
NCT Number NCT06605690
Lead Sponsor Liu Shu
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov